Atlas Trials

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

Clinical trial NCT05181995 · TERMINATED

Trial details

NCT number
NCT05181995
Sponsor
Aptinyx
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
PTSD
Start date
2021-12-13
Primary completion
2023-03-30
Enrollment
121

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.